New Heart Disease Drugs Fail to Show Expected Benefits

Medical researchers recently shared disappointing news regarding two new drugs that were expected to help prevent heart disease. Doctors had high hopes that these treatments would protect patients from heart attacks and strokes, but large studies showed that neither drug provided the expected benefits. These results were presented at the American Heart Association annual meeting in Chicago and published in the New England Journal of Medicine.

The first study looked at a drug called ziltivekimab. This medicine was designed to lower inflammation, which is the body's response to injury or infection. According to MedPage Today, researchers found that while the drug successfully lowered inflammatory markers in the blood, it did not reduce the number of heart attacks, strokes, or deaths in patients. Paul M. Ridker, a doctor at Harvard Medical School, noted that the patients in this study had advanced heart disease and kidney problems. He suggested that for these patients, the disease might have already reached a stage where anti-inflammatory drugs are no longer effective.

A second study focused on a different approach. Doctors tested a drug called pelacarsen, which was designed to lower levels of a protein in the blood called lipoprotein(a), or Lp(a). High levels of this protein have long been linked to a higher risk of heart disease. According to NPR, about one billion people worldwide have high levels of this protein. Steven Nissen, a cardiologist at the Cleveland Clinic who led the study, stated that he was shocked by the results. Although the drug successfully lowered Lp(a) levels by about 78 percent, patients who took the medicine did not have fewer heart attacks or strokes compared to those who took a placebo—a pill with no medicine in it used for comparison.

These results were unexpected because many experts believed these drugs would be major breakthroughs. Cardiovascular disease remains the leading cause of death in many developed countries, and doctors are constantly searching for new ways to help patients who already follow healthy habits. Many of these patients eat well, exercise, and keep their cholesterol and blood pressure under control, yet they still suffer from heart problems. Harlan Krumholz, a cardiologist at Yale University, described the failure of the pelacarsen study as "jarring" because the expectations for success were so high.

So, what went wrong? Researchers are currently trying to understand these results. Regarding the inflammation drug, Dr. Ridker explained that while genetic data suggested that the pathway being targeted was important, there is a difference between genetic influence and the ability to reverse a disease once it has started. He noted that the body's inflammatory systems are "exceptionally complex." For the Lp(a) study, some scientists are now questioning if high levels of this protein actually cause heart disease, or if it is simply a marker that appears when other problems are already present.

Despite these setbacks, experts remain committed to finding new solutions. Novartis, the company that made pelacarsen, stated that the study provides important information that will help guide future research. Meanwhile, Dr. Ridker noted that other studies on ziltivekimab are still ongoing for different groups of patients, and he remains optimistic about those trials. He also reminded patients that there are still effective ways to manage heart health. Clinicians can help patients reduce inflammation and risk through lifestyle changes, such as healthy eating, regular exercise, and stopping smoking. Additionally, existing medications like statins—drugs that lower cholesterol—have already been proven to improve outcomes for many people.

These findings serve as a reminder that medical science is a difficult process. Even when a treatment works exactly as intended in the laboratory, it may not always lead to better health outcomes in the real world. As researchers continue to study these complex diseases, they will use these results to refine their approach and look for new, more effective ways to protect patients in the future.